My Portfolio: [ Ссылка ]

Abbvie’s a pharmaceutical stock that’s been a leader in the healthcare industry since their spin-off from Abbott Laboratories in 2013. During this time, the company has been a very popular stock among dividend investors for a lot of really solid reasons. Abbvie is a dividend aristocrat, meaning they’ve grown their dividends every year for at least 25 consecutive years, when you include Abbott Laboratories dividend history. Historically speaking, Abbvie has almost always offered a higher dividend yield than the average dividend aristocrat, and they’ve also offered investors a pretty impressive amount of dividend growth.

According to Seeking Alpha’s metrics, Abbvie has crushed similar stocks in the same sector when it comes to dividend increases. Additionally ABBV has done really well from a total return perspective, offering really consistent share price growth. Since their IPO in 2013, their stock has delivered investors an average annual return of over 19%. You can see that a $10,000 investment right when they launched would leave you with over $72,000 today after 11 years and with reinvested dividends. But some recent developments have resulted in shareholders becoming skeptical of their future. Abbvie’s stock is currently down 11 and a half percent in the last month, and news that came out on Friday resulted in a drop of more than 4 and a half percent. I figured it would be a good idea to look into the status of this stock, which has some investors wondering what their future will look like.

свернуть